Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer.

Dushyanthen S, Teo ZL, Caramia F, Savas P, Mintoff CP, Virassamy B, Henderson MA, Luen SJ, Mansour M, Kershaw MH, Trapani JA, Neeson PJ, Salgado R, McArthur GA, Balko JM, Beavis PA, Darcy PK, Loi S
Nat Commun. 2017 8 (1): 606

PMID: 28928458 · PMCID: PMC5605577 · DOI:10.1038/s41467-017-00728-9

MeSH Terms (21)

4-1BB Ligand Animals Breast Neoplasms Cell Line, Tumor Cell Proliferation Female Humans Immunotherapy Lymphocytes, Tumor-Infiltrating Mammary Neoplasms, Animal MAP Kinase Kinase 1 MAP Kinase Kinase 2 MAP Kinase Signaling System Mice OX40 Ligand Protein Kinase Inhibitors Pyridones Pyrimidinones T-Lymphocytes T-Lymphocyte Subsets Triple Negative Breast Neoplasms

Connections (1)

This publication is referenced by other Labnodes entities:

Links